BMI and Preserved Ejection Fraction - Cardiovascular Update

Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER

European Journal of Heart Failure

DECEMBER 13, 2023

BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. In addition, dapagliflozin was safe and well-tolerated, irrespective of COPD status.

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Pulmonary Quality of Life

Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting

Circulation

JANUARY 22, 2025

Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%72%). With a BMI 35 kg/m2, lower rule-in thresholds (220 pg/mL) provided good specificity (88% [95% CI, 73%100%]; 93% [95% CI, 81%100%] and 100% in validation cohorts). Circulation, Ahead of Print.

Preserved Ejection Fraction

Preserved Ejection Fraction Outpatient Heart Failure BMI

GLP-1 Receptor Agonists Along With SGLT2 Inhibitors for HFpEF

American College of Cardiology

NOVEMBER 18, 2024

What is the incremental benefit in patients with heart failure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) â‰¥27?

Preserved Ejection Fraction

Preserved Ejection Fraction BMI Heart Failure Diabetes

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

University Hospitals Researcher Develops New Score System to Better Screen and Treat HFpEF Heart Failure Patients

DAIC

JULY 31, 2024

mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

Heart Failure

Heart Failure Preserved Ejection Fraction Research Hospital

Adiposity, fat-free mass and incident heart failure in 500 000 individuals

Open Heart

JULY 4, 2024

Overall, HF risk was more strongly associated with central adiposity (waist circumference (WC) adjusted for body mass index (BMI); HR 1.38, 95% CI 1.32 to 1.45) than general adiposity (BMI adjusted for WC; HR 1.22, 95% CI 1.16 Results Over a median follow-up of 13.8 years, there were 10 455 first-ever incident HF events. to 2.07).

Heart Failure

Heart Failure Preserved Ejection Fraction BMI

Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP?HF II trial

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased. Overall, 60.9%

Preserved Ejection Fraction

Preserved Ejection Fraction Obesity Heart Failure BMI

Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity

Circulation

NOVEMBER 17, 2024

Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5, Circulation, Ahead of Print.

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Obesity Quality of Life

Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial

Circulation

NOVEMBER 11, 2023

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg or placebo for 52 weeks.

Preserved Ejection Fraction

Preserved Ejection Fraction Quality of Life Obesity Heart Failure

Metabolic dysfunction and incidence of heart failure subtypes among Black individuals: The Jackson Heart Study

European Journal of Heart Failure

MARCH 30, 2025

We categorized participants based on MetS status and MetS severity scores (based on waist circumference [MetS-Z-WC] and body mass index [MetS-Z-BMI]).

Heart Failure

Heart Failure Preserved Ejection Fraction Biomarkers BMI

Abstract 4146852: Impact of Left Ventricular Diastolic Function in Pulmonary Arterial Hypertension Outcomes

Circulation

NOVEMBER 11, 2024

The H2FPEF score and probability were developed to assist in heart failure with preserved ejection fraction (HFpEF) diagnosis. Results:Overall, 140 participants were identified (age: 56±16 years; BMI: 30.04±8.04 kg/m2; 74% female) with normal left ejection fraction (LVEF: 63±9%). 2022 were included.

Pulmonary

Pulmonary Hypertension Preserved Ejection Fraction Outcomes

Hypertensive pregnancy disorder, an under‐recognized women specific risk factor for heart failure?

European Journal of Heart Failure

NOVEMBER 19, 2024

BMI, body mass index; CV, cardiovascular; CVD, cardiovascular disease; HELLP, haemolysis, elevated liver enzymes, low platelet count. Hypertensive disorders of pregnancy as a risk factor for heart failure.

Risk Factors

Risk Factors Heart Failure Hypertension Preserved Ejection Fraction

Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity

European Journal of Heart Failure

DECEMBER 13, 2023

BMI, body mass index; GLS, global longitudinal strain; LASct, left atrial contractile strain. Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heart failure with preserved ejection fraction. Association between epicardial adipose tissue (EAT) and cardiac dysfunction in severe obesity.

Obesity

Obesity Preserved Ejection Fraction BMI Heart Failure

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

JULY 25, 2023

2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2. These individuals tend to have a better prognosis when compared to both individuals with normal weight (BMI of 18.5 to 25 kg/m2) and underweight (BMI less than 18.5

Obesity

Obesity BMI Heart Failure Cardiovascular Disease

Abstract 4118122: Effect of Beta Blockers on Exercise Capacity, Diastolic Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction

Circulation

NOVEMBER 11, 2024

A multivariate logistic regression model was used to assess for statistically significant differences after controlling for potentially confounding variables including age, sex, BMI, AF, prior MI, COPD, DM, HTN, serum creatinine, and NYHA functional class.Results:A total of 320 patients were included in this analysis, with 230 on BB (72%).

Quality of Life

Quality of Life Preserved Ejection Fraction Exercise Heart Failure

Semaglutide Leads to Greater Weight Loss in Women than Men with HF, Improves HF Symptoms in Both Sexes

DAIC

JUNE 26, 2024

The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure ( HF ) with preserved ejection fraction (HFpEF). Our study sheds light on these differences and the consistent benefits of semaglutide for women and men.”

Preserved Ejection Fraction

Preserved Ejection Fraction Obesity BMI Heart Failure

Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER

Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting

GLP-1 Receptor Agonists Along With SGLT2 Inhibitors for HFpEF

Webinars

University Hospitals Researcher Develops New Score System to Better Screen and Treat HFpEF Heart Failure Patients

Adiposity, fat-free mass and incident heart failure in 500 000 individuals

Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP?HF II trial

Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity

Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial

Metabolic dysfunction and incidence of heart failure subtypes among Black individuals: The Jackson Heart Study

Abstract 4146852: Impact of Left Ventricular Diastolic Function in Pulmonary Arterial Hypertension Outcomes

Hypertensive pregnancy disorder, an under‐recognized women specific risk factor for heart failure?

Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Abstract 4118122: Effect of Beta Blockers on Exercise Capacity, Diastolic Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction

Semaglutide Leads to Greater Weight Loss in Women than Men with HF, Improves HF Symptoms in Both Sexes

Stay Connected